ProfileGDS5678 / 1421750_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 96% 96% 95% 95% 94% 93% 94% 94% 95% 95% 95% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4497395
GSM967853U87-EV human glioblastoma xenograft - Control 28.8597996
GSM967854U87-EV human glioblastoma xenograft - Control 38.813696
GSM967855U87-EV human glioblastoma xenograft - Control 48.7740995
GSM967856U87-EV human glioblastoma xenograft - Control 58.6261895
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.9253294
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.7462193
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.0986594
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0245594
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.5460795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.4444995
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6703795
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.5546895
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.5194895